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Abstract
Background: It is widely thought that widespread antibiotic use selects for community antibiotic resistance, though this has
been difficult to prove in the setting of a community-randomized clinical trial. In this study, we used a randomized clinical
trial design to assess whether macrolide resistance was higher in communities treated with mass azithromycin for trachoma,
compared to untreated control communities.
Methods and Findings: In a cluster-randomized trial for trachoma control in Ethiopia, 12 communities were randomized to
receive mass azithromycin treatment of children aged 1–10 years at months 0, 3, 6, and 9. Twelve control communities were
randomized to receive no antibiotic treatments until the conclusion of the study. Nasopharyngeal swabs were collected
from randomly selected children in the treated group at baseline and month 12, and in the control group at month 12.
Antibiotic susceptibility testing was performed on Streptococcus pneumoniae isolated from the swabs using Etest strips. In
the treated group, the mean prevalence of azithromycin resistance among all monitored children increased from 3.6% (95%
confidence interval [CI] 0.8%–8.9%) at baseline, to 46.9% (37.5%–57.5%) at month 12 (p=0.003). In control communities,
azithromycin resistance was 9.2% (95% CI 6.7%–13.3%) at month 12, significantly lower than the treated group (p,0.0001).
Penicillin resistance was identified in 0.8% (95% CI 0%–4.2%) of isolates in the control group at 1 year, and in no isolates in
the children-treated group at baseline or 1 year.
Conclusions: This cluster-randomized clinical trial demonstrated that compared to untreated control communities,
nasopharyngeal pneumococcal resistance to macrolides was significantly higher in communities randomized to intensive
azithromycin treatment. Mass azithromycin distributions were given more frequently than currently recommended by the
World Health Organization’s trachoma program. Azithromycin use in this setting did not select for resistance to penicillins,
which remain the drug of choice for pneumococcal infections.
Trial registration: http://www.ClinicalTrials.gov NCT00322972
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Antibiotic selection pressure is thought to be an important
mechanism of selecting for antibiotic resistance in populations [1].
High antibiotic use is correlated with antibiotic resistance in
ecological studies [2–10], and cross-sectional, cohort, and case-
control studies have confirmed these findings [11–13]. Although
these studies suggest that population-level antibiotic pressure is
associated with resistance, these study designs are subject to bias
[14,15]. A randomized controlled trial would provide the strongest
evidence for a causal relationship between community antibiotic
consumption and resistance.
Trachoma, caused by infection with ocular strains of Chlamydia
trachomatis, is the leading infectious cause of blindness worldwide.
The World Health Organization (WHO) endorses mass distribu-
tions of antibiotics as one component of an integrated trachoma
control strategy. Mass antibiotic treatment clears chlamydial
infection in both symptomatic and asymptomatic individuals, thus
reducing the infectious reservoir of disease [16]. Most programs
distribute community-wide azithromycin annually, though there is
evidence that the most severely affected communities may require
more frequent antibiotic distribution for trachoma elimination
[17–19].
Communities receiving mass azithromycin treatments for
trachoma are under intense antibiotic selection pressure. Although
chlamydial resistance has not been reported [20,21], nasopharyn-
geal pneumococcal resistance has been observed in uncontrolled
studies after a single azithromycin treatment, and after repeated
annual treatments [22–24]. Recently, we performed a population-
based, cluster-randomized clinical trial of mass azithromycin for
trachoma in Ethiopia [25]. In this study, entire communities were
randomized either to intensive azithromycin treatments, or to no
treatment, and monitored for trachoma. The trial also provided a
unique opportunity to further characterize the community-level
effects of antibiotic pressure on resistance. Here, we report
nasopharyngeal S. pneumoniae resistance in children before and
after frequent mass azithromycin treatments, and compare to
untreated control communities.
Methods
The study had approval from the Committee for Human
Research of the University of California, San Francisco, Emory
University, and the Ethiopian Science and Technology Commis-
sion. The study was carried out in accordance with the
Declaration of Helsinki and overseen by a Data Safety and
Monitoring Committee appointed by the National Institutes of
Health-National Eye Institute.
Setting
This study consists of a prespecified analysis from a cluster-
randomized clinical trial conducted between May 2006 and May
2007 in the Goncha Siso Enese woreda (district) of the Amhara
zone of Ethiopia [25]. As part of the clinical trial, 12 subkebeles
(administrative units) were randomized to receive quarterly
azithromycin treatment of children ages 1–10 y at months 0, 3,
6, and 9. Twelve control subkebeles were randomized to treatment
of the entire community at month 12. Subkebeles were randomly
chosen from an area of 72 contiguous subkebeles. This area
excluded the local town, where the prevalence of trachoma would
likely be low [26], and inaccessible communities (defined as those
greater than a 3-h walk from the furthest point available to a four-
wheel drive vehicle). The socioeconomic and demographic
characteristics of the included subkebeles were similar. The
randomization sequence was generated by Kathryn Ray with
the RANDOM and SORT functions in Excel (Version 2003) and
concealed until assignment. Participant enrollment and treatment
assignment was performed by BA. Each subkebele consisted of
approximately four to six state teams (administrative subunits),
termed ‘‘communities’’ for this report. All communities from the
randomized subkebeles were treated identically to minimize
contamination between study arms. One randomly chosen sentinel
community was monitored for trachoma (results described
elsewhere) [25]. In addition, nasopharyngeal S. pneumoniae
antibiotic resistance was assessed in the sentinel communities,
and is reported here (Figure 1; Texts S1 and S2).
Intervention
In the children-treated arm, all children aged 1–10 y were
offered one dose of directly observed oral azithromycin (20 mg/kg)
every 3 mo for 1 y (at months 0, 3, 6, and 9). Treatments were
offered to all children in the subkebele during a single antibiotic
campaign lasting several days, and all subkebeles in the study were
treated within several weeks of each other. In order to monitor for
a secular trend, a delayed treatment arm (control arm) was
enrolled at baseline, but not monitored until month 12, after
which all individuals aged 1 y and older were offered azithromycin
treatment. In both treatment groups, macrolide-allergic or self-
reporting pregnant individuals eligible for treatment were offered a
6-wk course of twice-daily 1% tetracycline ointment. Antibiotic
coverage was assessed by the antibiotic distributors against the
baseline census. For ethical reasons, other than the baseline
census, we collected no data from the control group until month
12 of the study.
Outcome Participants
We collected nasopharyngeal samples from ten randomly
selected children aged ,10 y from each sentinel community in
(1) the children-treated arm at baseline and month 12, and (2) the
control arm at month 12 only. Swabs were always collected just
before a mass azithromycin distribution; therefore, the swabs
collected at month 12 in the children-treated arm were collected
3 mo after the most recent treatment. The random sample was
redrawn at each visit, so children selected at baseline may or may
not have been selected again at month 12. An alternative list of
five additionally randomly selected children was available at each
visit, to be used if any of the first ten randomly selected children
had moved, died, or were traveling during the collection period.
Verbal informed consent was obtained from parents or guardians
for each child in the local language, Amharic.
Sample Collection
Nasopharyngeal swabs were preserved and transported using
skim milk-tryptone-glucose-glycerin medium, as previously de-
scribed [27]. Samples were kept on ice in the field and then in a
220uC freezer, and subsequently shipped to the United States on
ice. Samples arrived frozen, and were placed in a 280uC freezer
for up to 6 mo until processed.
Laboratory Studies
S. pneumoniae colonies were identified using selective media
(incubated at 35uCi n5 %C O 2) and optochin and bile solubility
testing. S. pneumoniae isolates were evaluated for antimicrobial
susceptibilities using Etest strips (bioMe ´rieux - AB Biodisk) placed
on Mueller-Hinton agar plates with 5% defibrinated sheep blood,
which were incubated at 35uCi n5 %C O 2 for 20–24 h before
determination of minimum inhibitory concentrations (MICs). S.
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PLoS Medicine | www.plosmedicine.org 2 December 2010 | Volume 7 | Issue 12 | e1000377Figure 1. Trial profile. 24 subkebeles were randomized to mass treatment of children, or to a control group that received delayed treatment after
the conclusion of the study. No sentinel communities were lost to follow-up, and none discontinued the intervention. All communities were included
in the analyses at 12 mo. *Reasons for not receiving allocated intervention included absent, moved, or death.
doi:10.1371/journal.pmed.1000377.g001
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MIC values were determined from the FDA-approved package
insert, using interpretation values for CO2 when provided. The
following MICs were used to define resistance: azithromycin (CO2)
($16 mg/ml), clindamycin (CO2)( .2 mg/ml), benzylpenicillin
($2 mg/ml), and tetracycline ($8 mg/ml). All susceptibility testing
was performed by a technician masked to study arm and time
point.
Genotyping
All azithromycin-resistant isolates underwent genotypic analysis
for the mefA gene (M phenotype, drug efflux) and ermB gene (MLSB
phenotype, ribosomal target modification). These two genes
account for the vast majority of azithromycin resistance [28–31].
PCR was performed using oligonucleotide primers to amplify a
348-bp segment containing the mefA gene or a 639-bp segment
containing the ermB gene element [32]. Positive controls for each
primer pair and a negative control strain (S. pneumoniae ATCC
49619) were included with all runs.
Statistical Analysis
Analyses were conducted at the community level. Antibiotic
coverage was defined as the proportion of children aged #10 y
who accepted treatment with azithromycin or tetracycline at each
time point, as determined from the baseline census. Note that
children aged under 1 y were not eligible for azithromycin
treatment, but were included in the coverage calculations since
they were monitored for resistance. S. pneumoniae carriage was
defined as the proportion of nasopharyngeal samples from which
S. pneumoniae was isolated. S. pneumoniae resistance was defined as
the proportion of S. pneumoniae isolates that displayed antibiotic
resistance. The mean prevalence of S. pneumoniae carriage and S.
pneumoniae resistance in children aged ,10 y was estimated from
the 12 sentinel communities of the children-treated arm at baseline
and 1 y, and from the control arm at 1 y. The average proportion
of resistant isolates that tested positive for ermB and mefA
determinants was calculated, using only those communities with
resistant isolates. Bias-corrected bootstrapped 95% confidence
intervals (CIs) were computed (10,000 repetitions). If there were no
observations for a proportion, exact binomial one-sided 97.5% CIs
were calculated, ignoring clustering. The prespecified primary
outcome compared the prevalence of resistance between commu-
nities in the treated and control arms at month 12 (Wilcoxon rank
sum test). An additional prespecified outcome was the comparison
of the prevalence of resistance within communities in the treated
arm comparing month 0 to month 12 (Wilcoxon signed-rank test).
Several non-prespecified analyses were also conducted. We
performed univariate mixed effects logistic regression on the
population of children colonized with pneumococcus, with the
presence of azithromycin resistance at 12 mo as the response
variable, and the treatment arm as the explanatory variable, while
clustering at the subkebele level. We calculated the prevalence of
antibiotic resistance among all monitored children, regardless of
whether pneumococcus was isolated. The intraclass correlation
(ICC) for the children-treated arm at 12 mo was calculated using
the loneway command in Stata. As an exploratory analysis, an r6c
contingency table (2 rows, 12 columns) was constructed plotting
the presence or absence of the mefA genetic determinant against
sentinel community, and a Fisher exact test was performed to test
whether mefA-positive isolates were evenly distributed among
communities. An identical analysis was performed for ermB.
Intention-to-treat analyses were performed for all statistical tests.
The trial had 90% power to detect a 30% difference between the
two groups, assuming 24 clusters randomized in a 1:1 allocation
ratio, a S. pneumoniae carriage rate of 80%, a type-I error rate of
0.05, an ICC of 0.05 (determined from a previous study [33]), and
a 50% prevalence of azithromycin resistance in the treated group
at 12 mo. All statistical analyses were performed with Stata version
10.0.
Results
Characteristics of Treatment Arms
The pretreatment characteristics of the children included in the
two study arms were not significantly different (Table 1). Among
children ages #10 y in the sentinel communities of the treated
group, azithromycin coverage at months 0, 3, 6, and 9 was 72.8%
(95% CI 67.6%–76.9%), 76.3% (72.2%–80.1%), 80.4% (77.9%–
2.9%), and 78.2% (75.2%–80.7%), and tetracycline coverage was
1.5% (0.6%–2.9%), 1.5% (0.6%–2.7%), 2.5% (1.1%–4.5%), and
4.8% (3.5%–6.2%), respectively. In the control arm, 34 children
were mistakenly treated in one subkebele at baseline, including 12
children from the sentinel community. This mistakenly treated
control sentinel community was retained in the control group for
all analyses.
S. pneumoniae Carriage and Antimicrobial Susceptibility
of Isolates
We collected a random sample of ten nasopharyngeal swabs
from each sentinel community in the children-treated group at
baseline and at month 12, and from each sentinel community in
the control group at month 12. In a single community in the
treated arm, all baseline samples were destroyed during a flood,
and one sample was lost at month 12. Baseline characteristics of
the community with missing data were not significantly different
from the other sentinel communities (unpublished data). S.
pneumoniae was isolated from 76 of 110 nasopharyngeal samples
collected from the treated arm before mass azithromycin
treatments (mean prevalence of S. pneumoniae carriage 69.1%
[95% CI 56.7%–81.7%]), and from 93 of 119 samples 12 mo after
the baseline treatment (78.0% [68.0%–86.7%]) (Table 2). Data
was collected from the control group at month 12 only; in this
untreated group, S. pneumoniae was isolated in 98 of 120
nasopharyngeal samples (81.7% [95% CI 75.8%–89.2%])
(Table 2).
Table 1. Pretreatment characteristics of children in the
children-treated group and the control group.
Characteristic Children-Treated Control
a
Population per community
b 100.5 (80.1–120.9) 104.2 (92.7–115.7)
Age, y
b 4.4 (4.3–4.5) 4.5 (4.3–4.6)
Female
b 49.3% (46.6%–52.0%) 48.7% (47.1%–50.2%)
Clinically active trachoma
c 69.0% (57.5%–80.5%) 70.0% (62.2%–77.6%)
Ocular chlamydia
d 48.4% (42.9%–53.9%) 45.6% (36.7%–54.5%)
Estimates represent the mean, shown with 95% CIs in parentheses.
aObservations for the control group are, by design, from the 1-y time point.
bDemographic characteristics reported for children ages ,10 y from all study
communities (state teams).
cDefined as follicular trachomatous inflammation (TF) and/or intense
trachomatous inflammation (TI) by the WHO simplified grading scale; reported
for children ages 1–10 y in the sentinel communities [45].
dAs detected by PCR; reported for children ages 1–10 y in the sentinel
communities.
doi:10.1371/journal.pmed.1000377.t001
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,10 y is shown for the population of all swabbed children, and for
the population of children from which pneumococcus was isolated
(Table 2). Prior to treatment, three of the 11 sentinel communities
in the treated group demonstrated azithromycin-resistant S.
pneumoniae isolates, and a total of four of the 76 isolates were
resistant (mean prevalence among pneumococcal isolates, 6.3%
[95% CI 1.0%–15.7%]) (Table 2). After four azithromycin
treatments within 1 y, azithromycin resistance was observed in
all 12 communities, with 56 of 93 isolates demonstrating resistance
(intraclass correlation [ICC] =0.11 [95% CI 0–0.29]; mean
prevalence 62.3% [95% CI 49.1%–75.4%], p=0.003 compared
to baseline, prespecified analysis). In the control group at month
12, nine of 12 communities exhibited azithromycin-resistant
strains, with 11 of the 98 isolates testing positive for resistance
(mean prevalence 11.6% [95% CI 6.9%–17.1%], p=0.0001
compared to children-treated group at 1 y, prespecified analysis).
Children from communities treated with quarterly mass antibiotics
were more likely to be colonized with macrolide-resistant
pneumococcus compared to children from untreated communi-
ties; OR 13.2 (95% CI 5.5–31.9; non-prespecified analysis).
Significant increases in clindamycin and tetracycline resistance
were detected after mass antibiotic distributions (Table 2). In the
treated arm, clindamycin resistance increased from one resistant
isolate before mass treatment (mean prevalence 1.5% [95% CI
0%–6.1%]) to 16 resistant isolates after four quarterly treatments
(mean prevalence 16.9% [6.9%–27.9%], p=0.02), though this
level was not significantly higher than time-matched untreated
controls (four resistant isolates, corresponding to 3.9% of isolates
[95% CI 1.0%–8.6%], p=0.10). Before treatment, children
carried strains resistant to tetracycline more than any other
antibiotic tested, with 11 resistant isolates at the baseline visit in
the children-treated arm (15.2% of all isolates [95% CI 5.6%–
28.1%]). By month 12, 34 tetracycline-resistant isolates were
recovered in the treated group (mean prevalence 35.5% [95% CI
24.7%–45.2%], p=0.04), though this was not significantly greater
than that of time-matched untreated controls (21 resistant isolates;
mean prevalence 21.5% [13.9%–28.7%], p=0.07).
The only antibiotic tested that did not demonstrate the
emergence of significant resistance was benzyl-penicillin. Penicillin
resistance in the community was rare, with no resistant isolates
observed in the children-treated group, either before or after mass
antibiotic treatments. In the untreated control group, a single
resistant isolate was identified, which corresponded to 1.0% (95%
CI 0%–5.2%) of the population.
Genotyping of Azithromycin-Resistant Isolates
The average proportion of azithromycin-resistant strains testing
positive for the two most common genetic elements encoding
resistance is shown in Table 3. All ermB+ isolates, including 17
mefA2/ermB+ isolates and 4 mefA+/ermB+ isolates, also had high-
level azithromycin resistance by Etest (MIC.256). Azithromycin
resistance was moderate in the 49 mefA+/ermB2 isolates (range 24
to .256; median =192). In comparison, the 196 susceptible
isolates had azithromycin MICs ranging from 0.19 to 2
(median=1).
Four azithromycin-resistant isolates were detected at baseline in
the children-treated group. The three isolates with mefA resistance
at baseline came from two communities, and each of these
communities demonstrated only mefA resistant strains at month 12.
The ermB genetic determinant was seen in a separate community
at baseline; at the 12-mo follow-up, this community demonstrated
predominantly ermB resistance, but also a single isolate with both
determinants. In seven of the 12 treated communities at 12 mo, all
resistant isolates displayed the mefA genetic determinant (p=0.09
for 2612 contingency table). In contrast, there was only one
Table 2. Nasopharyngeal pneumococcal carriage and resistance in children aged ,10 y in the children-treated group (pre- and
post-treatment), and the untreated control group.
Carriage or Resistance Azithromycin-Treated (n=Communities) Control (n=Communities)
Baseline
Pretreatment n=11
Month 12 Post-
treatment n=12 p-Value
a
Baseline (Not
Sampled by Design)
Month 12
Untreated n=12 p-Value
b
S. pneumoniae carriage
c 69.1% (56.7%–81.7%) 78.0% (68.0%–86.7%) 0.09 — 81.7% (75.8%–89.2%) 0.72
Azithromycin resistance
Swabs
d 3.6% (0.8%–8.9%) 46.9% (37.5%–57.5%) 0.003 — 9.2% (6.7%–13.3%) ,0.0001
Isolates
e 6.3% (1.0%–15.7%) 62.3% (49.1%–75.4%) 0.003 — 11.6% (6.9%–17.1%) 0.0001
Clindamycin resistance
Swabs
d 1.5% (0%–6.3%) 13.3% (6.7%–23.3%) 0.02 — 3.3% (0.8%–8.3%) 0.10
Isolates
e 1.5% (0%–6.1%) 16.9% (6.9%–27.9%) 0.02 — 3.9% (1.0%–8.6%) 0.10
Penicillin resistance
Swabs
d 0% (0%–3.3%) 0% (0%–3.1%) — — 0.8% (0%–4.2%) 0.32
Isolates
e 0% (0%–4.7%) 0% (0%–3.9%) — — 1.0% (0%–5.2%) 0.32
Tetracycline resistance
Swabs
d 10.0% (4.5%–18.2%) 28.4% (19.4%–38.4%) 0.02 — 17.5% (11.7%–24.2%) 0.11
Isolates
e 15.2% (5.6%–28.1%) 35.5% (24.7%–45.2%) 0.04 — 21.5% (13.9%–28.7%) 0.07
Estimates represent the mean of sentinel communities, shown with 95% confidence intervals in parentheses.
aWilcoxon signed rank test, comparing pre- and post-treatment in the treated arm.
bWilcoxon rank sum test, comparing post-treatment treated arm with untreated control arm.
cProportion of nasopharyngeal samples from which S. pneumoniae was isolated.
dProportion of swabbed children who were classified as resistant.
eProportion of pneumococcal isolates that were classified as resistant.
doi:10.1371/journal.pmed.1000377.t002
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exhibited the ermB determinant (p=0.01 for 2612 contingency
table). The prevalence of the mefA determinant in the children-
treated group at month 12 did not differ from the prevalence of
mefA in the children-treated group at baseline (p=0.32), or from
the control group at month 12 (p=0.91).
Discussion
This cluster-randomized clinical trial demonstrates that fre-
quent antibiotic use selects for community-level antibiotic
resistance. In communities randomized to four azithromycin
treatments within 1 y, azithromycin resistance was observed in
47% of all swabbed children and 62% of children colonized with
pneumococcus; this was significantly higher than untreated control
communities, in which resistance was found in 9% of swabbed
children and 12% of children colonized with pneumococcus.
Genotype analyses were consistent with the widely accepted theory
that antibiotic selection pressure increases community antibiotic
resistance by reducing susceptible bacterial strains and allowing
clonal expansion of existing resistant strains.
Numerous ecological, analytic, and interventional studies have
suggested that population-level antibiotic pressure selects for
antibiotic resistance [34–36]. However, it has been difficult to rule
out the possibility of bias in many of these studies, since antibiotic
use in a population is difficult to quantitate, resistance testing is
rarely population based, and unmeasured confounders cannot be
ruled out. The study design used here had several advantages that
helped minimize bias. First, our knowledge of the degree of
antibiotic use was extremely accurate. This study was conducted in
a rural region in Ethiopia with infrequent background macrolide
use. A large, known amount of oral azithromycin was distributed to
treated communities, and treatment was directly observed. Second,
the study was a randomized controlled trial, which greatly reduces
the possibility of an association caused by unmeasured confounders.
Third, this study was cluster randomized. Although a previous
clinical trial showed antibiotic resistance in individuals using
macrolides [36], the cluster randomization of this study allows
analysis of community-level antibiotic resistance. Furthermore, the
likelihood of contamination from surrounding communities was
reduced by randomizing government districts (subkebeles), and
treating all communities in the district identically. Finally, bias was
reduced by performing population-based monitoring on a random
sample of children.
Antibiotic selection pressure is thought to increase community
antibiotic resistance by reducing susceptible bacterial strains and
shifting the competitive balance in favor of existing resistant strains
[1]. The distribution of the mefA and ermB genetic determinants in
this study suggests that clonal expansion of resistant strains
occurred. For example, the three communities with a specific
genetic element at baseline demonstrated a greater prevalence of
that same determinant after treatment. In addition, genes
encoding resistance were often present as an ‘‘all or none’’
phenomenon in a particular community, suggesting the spread of
existing genetic determinants, rather than development of new
ones. However, given the wide CIs around the prevalence of mefA
and ermB, these results should be interpreted with caution.
Although we did not follow communities after treatments were
stopped, there is evidence to suggest that pneumococcal resistance
is transient in areas with endemic trachoma. In an uncontrolled
study of a single community in Australia, 35% (10/29) of treated
children exhibited macrolide resistance 2 mo after a single dose of
azithromycin, but only 6% (2/34) did so 6 mo later [22]. Although
this community did not receive mass azithromycin—approximate-
ly half of children received azithromycin—the study nonetheless
suggests that resistance fades after antibiotic selection pressure is
removed. In other studies, macrolide resistance was observed in
only 5% of children 6 mo after the last of two or three annual mass
treatments [23,24]. These findings were corroborated by a
population-based study in Ethiopia, in which the prevalence of
macrolide resistance decreased dramatically after cessation of mass
azithromycin treatments—from 77% after the last of six biannual
mass treatments, to 21% by 2 y after the final treatment [33].
In this community-randomized clinical trial, quarterly azithro-
mycin treatment of children was clearly effective in reducing
ocular chlamydia [25]. Here, however, we report that more
frequent mass treatments also select for pneumococcal resistance.
It is notable that even the periodic treatments of this study were
sufficient to select for resistant strains, at least in this rural
Ethiopian setting with presumably efficient interhost transmission.
Fortunately, any negative impact is tempered by several factors.
First, resistance to penicillins, which would serve as first-line
therapy for S. pneumoniae infections and are widely available and
used in the study area, was not detected. Second, macrolides are
rarely used in the region, based upon a survey of pharmacies (BA,
unpublished data). Third, azithromycin resistance appears to be
transient in similar communities once mass treatments are stopped
[22,33]. Fourth, the clinical significance of azithromycin resistance
is unclear. There have been no reports of increased invasive
pneumococcal disease or increased mortality in areas treated with
mass azithromycin. To the contrary, a concomitant trial found
that mass azithromycin distributions may even reduce childhood
Table 3. Genotypic characteristics of azithromycin-resistant isolates from children aged ,10 y old in the treated group (pre- and
post-treatment), and the untreated control group.
Genetic Determinant Azithromycin Treated (n=Communities) Control (n=Communities)
Baseline
Pretreatment n=11
Month 12 Post-
treatment n=12 p-Value
a
Baseline (Not
Sampled by Design)
Month 12
Untreated n=12 p-Value
b
mefA+/ermB2 66.7% (0%–100%) 72.8% (52.8%–89.5%) 0.32 — 66.7% (36.0%–100%) 0.91
mefA2/ermB+ 33.3% (0%–100%) 19.4% (7.1%–34.4%) 0.32 — 33.3% (10.0%–72.7%) 0.81
mefA+/ermB+ — 6.6% (2.1%–13.9%) — —
mefA2/ermB2 — 1.2% (0%–5.6%) — —
Estimates represent the mean proportion of azithromycin-resistant isolates, shown with 95% CIs in parentheses.
aWilcoxon signed rank test, comparing pre- and post-treatment in the treated arm.
bWilcoxon rank sum test, comparing post-treatment treated arm with untreated control arm.
doi:10.1371/journal.pmed.1000377.t003
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every 3 mo—much more frequently than the annual treatments
recommended by WHO guidelines. This study is quite different
from previous studies, which have monitored pneumococcal
resistance after much lower levels of antibiotic selection pressure.
In particular, this study cannot be extrapolated to the case of
repeated annual mass treatments, for which pneumococcal
macrolide resistance has never been shown to exceed 5% by
6 mo after treatment [23,24]. Likewise, this study cannot be
generalized to the case of a single mass azithromycin distribution,
for which other studies have found at most only a single isolate of
pneumococcal macrolide resistance between 6–12 mo after a
community-wide treatment [38,39].
The beneficial effects of mass azithromycin treatments for
trachoma are very clear. Mass azithromycin distributions for
trachoma have been tremendously successful in reducing the
prevalence of ocular strains of chlamydia, and may even result in
the elimination of infection in some areas [18,40–42]. These
activities will be instrumental in reducing blindness due to
trachoma. The adverse effects of mass treatments are much less
certain. Although we show considerable nasopharyngeal macro-
lide resistance following frequent mass azithromycin in this study,
there is good reason to think that the clinical impact of resistance is
minimal, as discussed above. We believe that the known benefits of
mass azithromycin treatments clearly outweigh any uncertain
adverse effects, and that trachoma programs should continue to
distribute mass azithromycin treatments.
This study has several limitations. We did not collect baseline
nasopharyngeal samples in the control group, since we did not
want to mislead participants, who might have construed swabbing
as treatment. Note, however, that because treatment group was
randomly assigned, baseline measurements are not necessary for
between-group comparisons. We did not collect cultures from
other sites to monitor for invasive pneumococcal diseases such as
meningitis, pneumonia, or bacteremia. We do not have follow-up
data for these communities. We have not performed a genetic
analysis of pneumococcal strains, though we do plan on
completing such an analysis in the future. This study was
performed in Ethiopian communities with very high rates of
pneumococcal carriage. Although this rate of pneumococcal
carriage is the norm in much of Africa, it is higher than that
seen in most industrialized countries [43,44]. However, our
findings are consistent with many studies conducted in developed
countries [2–12], which suggests that the central finding of this
study—that community level S. pneumoniae resistance increases with
antibiotic use—is not specific to Ethiopia, but is generalizable to
other settings.
This study demonstrates the importance of antibiotic selection
pressure for community antibiotic resistance. Although we found a
considerable amount of pneumococcal macrolide resistance in
children treated with mass azithromycin treatments every 3 mo,
this finding has no bearing on current trachoma control activities,
which use less frequent antibiotic distributions, and which likely
select for far less pneumococcal resistance [22–24,38,39]. Our
findings nonetheless highlight the importance of continued
monitoring for the secondary effects of mass oral antibiotic
distributions.
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Background. In 1928, Alexander Fleming discovered
penicillin, the first antibiotic (a drug that kills bacteria). By
the early 1940s, scientists were able to make large quantities
of penicillin and, in the following decades, several other
classes of powerful antibiotics were discovered. For example,
erythromycin—the first macrolide antibiotic—was
developed in the early 1950s. For a time, it looked like
bacteria and the diseases that they cause had been defeated.
But bacteria rapidly become resistant to antibiotics. Under
the ‘‘selective pressure’’ of an antibiotic, bacteria that have
acquired a random change in their DNA that allows them to
survive in the antibiotic’s presence outgrow nonresistant
bacteria. What’s more, bacteria can transfer antibiotic
resistance genes between themselves. Nowadays, antibiotic
resistance is a major public health concern. Almost every
type of disease-causing bacteria has developed resistance to
one or more antibiotic in clinical use and multi-drug resistant
bacteria are causing outbreaks of potentially fatal diseases in
hospitals and in the community.
Why Was This Study Done? Although epidemiological
studies (investigations of the causes, distribution, and
control of disease in population) show a correlation
between antibiotic use and antibiotic resistance in
populations, such studies cannot prove that antibiotic use
actually causes antibiotic resistance. It could be that the
people who use more antibiotics share other characteristics
that increase their chance of developing antibiotic resistance
(so-called ‘‘confounding’’). A causal link between antibiotic
use and the development of antibiotic resistance can only be
established by doing a randomized controlled trial. In such
trials, groups of individuals are chosen at random to avoid
confounding, given different treatments, and outcomes in
the different groups compared. Here, the researchers
undertake a randomized clinical trial to assess whether
macrolide resistance is higher in communities treated with
azithromycin for trachoma than in untreated communities.
Azithromycin—an erythromycin derivative—is used to treat
common bacterial infections such as middle ear infections
caused by Streptococcus pneumoniae. Trachoma—the
world’s leading infectious cause of blindness—is caused by
Chlamydia trachomatis. The World Health Organization’s
trachoma elimination strategy includes annual azithromycin
treatment of at-risk communities.
What Did the Researchers Do and Find? In this cluster-
randomized trial (a study that randomly assigns groups of
people rather than individuals to different treatments), 12
Ethiopian communities received mass azithromycin
treatment of children aged 1–10 years old at 0, 3, 6, and 9
months, and 12 control communities received the antibiotic
only at 12 months. The researchers took nasopharyngeal
(nose and throat) swabs from randomly selected treated
children at 0 and 12 months and from randomly selected
control children at 12 months. They isolated S. pneumoniae
from the swabs and tested the isolates for antibiotic
susceptibility. 70%–80% of the children tested had S.
pneumoniae in their nose or throat. In the treated group,
3.6% of monitored children were carrying azithromycin-
resistant S. pneumoniae at 0 months, whereas 46.9% were
doing so at 12 months—a statistically significant increase.
Only 9.2% of the monitored children in the untreated group
were carrying azithromycin-resistant S. pneumoniae at 12
months, a significantly lower prevalence than in the treated
group. Importantly, there was no resistance to penicillin in
any S. pneumoniae isolates obtained from the treated
children at 0 or 12 months; one penicillin-resistant isolate
was obtained from the control children.
What Do These Findings Mean? These findings indicate
that macrolide resistance is higher in nasopharyngeal S.
pneumoniae in communities receiving intensive azithromycin
treatment than in untreated communities. Thus, they
support the idea that frequent antibiotic use selects for
antibiotic resistance in populations. Although the study was
undertaken in Ethiopian communities with high rates of
nasopharyngeal S. pneumoniae carriage, this finding is likely
to be generalizable to other settings. Importantly, these
findings have no bearing on current trachoma control
activities, which use less frequent antibiotic treatments and
are less likely to select for azithromycin resistance. The lack of
any increase in penicillin resistance, which is usually the first-
line therapy for S. pneumoniae infections, is also reassuring.
However, although these findings suggest that the benefits
of mass azithromycin treatment for trachoma outweigh any
potential adverse affects, they nonetheless highlight the
importance of continued monitoring for the secondary
effects of mass antibiotic distributions.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000377.
N The Bugs and Drugs website provides information about
antibiotic resistance and links to other resources
N The US National Institute of Allergy and Infectious Diseases
provides information on antimicrobial drug resistance and
on diseases caused by S. pneumoniae (pneumococcal
diseases)
N The US Centers for Disease Control and Prevention also
have information on antibiotic resistance (in English and
Spanish)
N The World Health Organization has information about the
global threat of antimicrobial resistance and about
trachoma (in several languages)
N More information about the trial described in this paper is
available on ClinicalTrials.gov
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